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Summary The growth inhibitory effects, the reduction of [3H]-TdR incorporation and the perturbation of
the cell cycle induced by the new agent mitozolomide on the M14 human melanoma cell line and on the
SW626 human ovarian cancer cell line were compared to those produced by BCNU. Flow cytometry showed
an interesting difference: at the high concentration mitozolomide induced an accumulation of cells in S middle
and S late-G2-M phase of the cell cycle whereas BCNU caused only a block in S late-G2-M. Further studies
were aimed at investigating the susceptibility of freshly isolated human ovarian cancer cells to
pharmacologically reasonable mitozolomide concentrations. Only in one out of 16 primary cultures of human
ovarian cancers was mitozolomide able to induce cell cycle perturbation, suggesting that ovarian carcinoma
cells may not be sensitive to this drug.
Mitozolomide(M),(NSC353451)(Stevens etal., 1984)
or 8-carbamoyl-3-(2-chloroethyl)-imidazo-[5,1-d]-l,
2,3,5-tetrazin-4(3H)-one, is a new anticancer
agent which has shown striking activity against
rodent tumors (Hickman et al., 1985). Its mechanism
of action appears related to the formation of DNA
interstrand-cross-links (DNA-ISC) in a manner
similar to that described for chloroethylnitrosoureas
(Gibson et al., 1984a,b).
Like the chloroethylnitrosoureas, M does not
produce DNA-ISC in cells which are able to
remove the crosslinkable monoadducts bound to 06
of guanine (i.e. cells with MER+ phenotype)
(Gibson et al., 1984b). On the other hand, in
contrast to the most commonly used chloro-
ethylnitrosoureas (e.g. BCNU), M shows no
carbamylating activity (Stevens et al., 1984; Horgan
& Tisdale, 1984) and this may perhaps explain
some of the differences in its pharmacological
effects.
In this study we compared the antiproliferative
effects and the perturbation of the cell cycle
produced by M and BCNU on the human
melanoma cell line, M14, and on the ovarian
carcinoma cell line, SW626, and investigated the
effects of M on 16 primary cultures of human
ovarian cancer cells freshly isolated from patients.
Materials and methods
SW626, a human ovarian cancer cell line (Fogh et
al., 1977a,b), was grown at 37°C in air plus 5%
CO2 in RPMI 1640 supplemented with 10% FCS,
2mm L-glutamine (Gibco Europe, Glasgow, UK),
10 mM NaHCO3, buffered with HEPES 20mM
(Merck, Darmstadt, W. Germany).
The human melanoma cell line M14 (Golub et
al., 1976), was also grown in RPMI 1640 but
without HEPES.
The effects of M were studied in primary cultures
derived from 6 primary ovarian adenocarcinomas, 2
omental metastases and 8 ascitic fluids from 13
patients. The patients' main characteristics are
shown in Table I. In patient no. 9 two paracenteses
were performed at intervals of one month. Tumour
biopsy specimens were collected in PBS containing
100U ml -1 penicillin and 100pigml - 1 streptomycin
(Gibco Europe, Glasgow, UK). Within 3 h of
primary surgery, tumour tissue fragments were
disaggregated by treatment with a 0.3% collagenase
solution (Collagenase type 1, Sigma Chemical
Company, St. Louis, USA) for 40min at 37°C
under continuous stirring. Cell suspension was
centrifuged, washed in PBS then resuspended in
growth medium. Tumour cell suspensions con-
taminated by RBC and/or leucocytes were further
processed as for ascitic fluids.
The ascitic fluids were collected in heparinized
bottles and the cells were separated by centri-
fugation. A first gradient with 100% of Ficoll-
Hypaque (d= 1.077; MSL, Eurobio, Paris) was
performed (600g for 20min) to remove RBC
contamination and debris. In cases of gross
lymphocyte and granulocyte contamination, a
second discontinuous gradient (75% Ficoll-
Hypaque, layered on 100% Ficoll-Hypaque) was
performed. After these steps, in all cases, tumour
cells were freed of macrophages by adhesion on
plastic culture dishes. Final cell suspensions,
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Table I Patients' characteristics
FIGO Histological Previous
Pt. No. Age PS staging Histology differentiation chemotherapy
1 50 100 III Serous Poorly differentiated None
2 68 80 III Serous Poorly differentiated None
3 54 90 III Serous Poorly differentiated None
4 63 90 III Serous Moderately differentiated None
5 57 100 III Serous Poorly differentiated None
6 57 70 IV Endometrioid Poorly differentiated None
7 62 90 III Serous Poorly differentiated None
8 50 80 III Serous Moderately differentiated DDP
9 60 80 III Serous Moderately differentiated PAC
10 52 90 III Serous Poorly differentiated PAC
11 60 80 III Serous Poorly differeintiated PAC
12 62 90 III Mucinous Poorly differentiated PAC
13 47 100 III Serous Poorly differentiated PAC
DDP=cis-dichlorodiammineplatinum.
PAC=cis-dichlorodiammineplatinum +cyclophosphamide+doxorubicin.
containing more than 70% viable cells (erythrosine
dye test) were seeded at 70,000cellscm-2 in 24-well
multiwell tissue culture plates (Falcon, Becton
Dickinson Labware, Oxnard, CA, USA) (Morasca
et al., 1983). The medium for human tumour cells
was the same as that for SW626 cells.
For the in vitro treatment, M (kindly supplied
by Prof. M.F.G. Stevens, Aston University,
Birmingham, UK or by Dr C.G. Newton, May and
Baker Ltd, Dagenham, Essex, UK) was dissolved in
medium plus dimethylsulfoxide (DMSO) to obtain
a maximal concentration of 0.0025% DMSO,
which is not toxic to the cells, and left in contact
with the cells for 24h; BCNU (Kindly supplied by
the Division of Cancer Treatment, NCI, Bethesda,
Md, USA) was dissolved in ethanol to obtain a
maximal concentration of 1% and left in contact
with the cells for 24h. After that cultures were
drained, washed in PBS and filled with fresh
growth medium for 72h (recovery time). The
cytotoxic effects of M and BCNU were evaluated
after treatment and/or recovery by two different
methods:
(a) as inhibition of thymidine [3H]-TdR incor-
poration, adding 0.5,uCi [3H]-TdR sp. act.
1.9 Ci mm- 1 (Schwarz Mann, Orangeburg) to the
well for the last hour of treatment or recovery time.
At the end of incubation cells were washed twice
with PBS, lysed by 1% sodium dodecylsulfate
(SDS) and counted in a toluene-based phosphorus
scintillation fluid with a Packard Tricarb 3400
scintillator;
(b) as a reduction in the cell count, using a
Coulter Counter model ZB (Coulter Electronics,
Ltd, UK).
Controls and each treatment group comprised
8-10 replicate cultures. Statistical analysis was done
by Dunnett's test using a Hewlett-Packard 85
computer (Colombo et al., 1986).
Flow cytometry studies were performed on a 30L
cytofluorograph (Ortho Instruments, US). Cells in
culture were washed with PBS after drug treatment
or recovery and directly stained with 2ml of
propidium iodide (PI) solution containing
50 ugml-1 PI (Calbiochem Behring Co, USA) in
0.1% sodium citrate, 25,ul 1% nonidet P40 as
detergent (Sigma) and 25kI RNAse O.5 ugml-1 in
water (Calbiochem Behring Co, USA) at room
temperature for 30-40min. With this method nuclei
were dislodged from cells adhering to the plastic
surface of the 24-well multiwell and entered into
suspension without the cells having to be suspended
(Colombo et al., 1986).
The fluorescence pulse was detected in a spectral
range between 580 and 750nm. The coefficient of
variation (CV) of the GI peak of the cells was 3-
4%.
Each cytofluorimetric assay was performed with
2-3 x 105 cells, and the percentage of the cell cycle
phases was calculated by the method of Krishan &
Frei (1976).
To determine the DNA index, human leucoytes
from freshly collected blood were used as standard.
The standard was run before and after the sample
to check for drifting of the laser output. The CV of
the leucocytes was between 1.5-2.5%. Ploidy was
expressed as DNA index, representing the ratio
between the GI peak of ovarian cancer cells and
the GO/GI peak of leucocytes (Erba et al., 1985).
Results
Figures 1 and 2 illustrate the effects of 24h
treatment with M and BCNU on M14 humanMITOZOLOMIDE ACTIVITY ON HUMAN CANCER CELLS
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Figure 1 Effects of M (@) and BCNU (0) after 24h treatment at concentrations of 1, 10 and 50 igml 1 on
M14 human melanoma cell line, evaluated as reduction in the number of cells (left panel) and as inhibition of
[3H]-TdR incorporation (right panel). Each value is the mean (±s.e.) of 8 replications.
100- 24 h treatment . I.%. IL
C
0
._
0 0
C
10 50 100
,ug ml-'1
24 h treatment + 72 h recovery I
T-
0
0 .O
100
80
60
40
20
0
10
,ug ml-'
100
24 h treatment + 72 h recovery
10
jig ml-'
50 100
Figure 2 Effects of M (@) and BCNU (0) after 24h treatment at concentrations of 1, 10 and 50pigml-1 on
SW626 human ovarian cancer cell line evaluated as reduction in the number of cells (left panel) and as
inhibition of [3H]-TdR incorporation (right panel). Each value is the mean (± s.e.) of 8 replications.
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melanoma cells and on SW626 human ovarian
cancer cells. In M14 cells M and BCNU caused an
overlapping inhibition of cell growth and only
slight differences in the [3H]-TdR incorporation.
In SW626 cells M appeared moderately more
effective than BCNU. M caused greater cell growth
inhibition, the difference being statistically signi-
ficant (P<0.01) 72h after drug treatment with
lOugm1-1. On both cell lines 50ugml-1 M or
0
U)
0
0
6 z
BCNU caused very similar inhibition of cell growth
and [3H]-TdR incorporation and these effects were
in fact stronger after 72h recovery time.
The effects of M and BCNU on the cell cycle of
M14 and SW626 were assessed by the flow
cytometric technique (Figures 3 and 4). Both drugs
caused an accumulation of cells in premitotic phase.
This effect was only slight at 1 gml -m1, clear at
I0pgml -1 and very marked at 50pgml-1. At the
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Figure 3 Effects of 24h M and BCNU treatment at concentrations of 1, 10 and 50pgml-1 on cell cycle
phase distribution in M14 human melanoma cell line.
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Figure 4 Effects of 24h M and BCNU treatment at concentrations of 1, 10 and 50jigml-P on cell cycle
phase distribution in SW626 human ovarian cancer cell line.
highest concentration M induced an accumulation
of cells in SM and SLG2M, whereas BCNU caused
an arrest only in SLG2M.
The activity of M was tested on 16 primary
cultures of human ovarian cancer cells from 13
patients. Tables II and III show the results of flow
cytometry analysis in ovarian cancer cells, derived
from previously untreated or treated patients, after
24h M treatment. When possible [3H]-TdR
incorporation after 24h drug treatment was also
evaluated. Only in case no. 3 was the cell cycle
perturbed, with an accumulation of cells in the SE
and SM phases. The slow progression through the
S phase was consistent with the marked reduction
of [3H]-TdR incorporation observed in this case
(P<0.01 at 1 and 10ugml-1 M concentrations).
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Table II Effects of M on the distribution in G1, S early (SE), S middle (SM), and S late +G2+Mitosis
(SLG2M) and on [3H]-TdR incorporation of human ovarian cancer cells (growing in primary culture) derived
from patients previously untreated with antineoplastic agents. Cells were treated for 24h.
Mitozolomide [3H]-TdR
Pt. no. Sample GJ SE SM SLG2M pUgml-1 DNA index % ofcontrol
1 Primary tumour 57 12 12 19 control 1.30
56 13 11 20 0.1 100
45 18 12 25 1 100
44 19 12 25 10 90
2 Ascitic fluid 64 4 7 25 control 1.20
78 44 3 15 0.1 85
74 3 4 19 1 84
70 4 5 21 10 70a
3 Metastasis 42 10 10 38 control 1.87
35 18 21 25 1 37b
38 18 23 21 10 28
4 Primary tumour 69 5 5 21 control 1.27
71 5 6 18 1
68 5 5 22 10
S Primary tumour 55 12 11 22 control 1.47
53 14 12 21 1
48 17 12 23 10
6 Primary tumour 71 8 8 13 control 1.80
71 8 8 11 1
72 7 9 12 10
6a Ascitic fluid 61 10 13 16 control 1.80
58 9 15 18 0.1
54 15 15 16 1
57 10 13 20 10
7 Primary tumour 36 18 16 30 control 1.00
42 16 16 26 1
34 19 16 31 10
DNA index was determined as
test. ap<0.05; bp<0.01.
described in Materials and methods. Statistical analysis was by Dunnett's
Discussion
As previously reported on murine Lewis lung
carcinoma in vivo (Broggini et al., 1986) and in vitro
(Horgan et al., 1983) M causes an accumulation of
cells in the S late+G2M phase of the cell cycle.
At a high concentration M, unlike BCNU, also
produces an accumulation of cells in SM phase.
This may be related to quantitative or qualitative
differences in the binding of the two drugs to DNA
and possibly to differences in DNA damage and
repair. That the biochemical features of M and
BCNU differ is not suprising considering that
BCNU causes protein carbamylation whereas M
does not (Hickman et al., 1985). It is known that
the formation of DNA-ISC after chloroethylnitro-
soureas treatment involves a first rapid alkylation
of O6guanine (i.e. chloroethylation or hydroxyethyl-
ation) followed by a second reaction with a
cytosine located on the opposite strand of DNA
(Erickson et al., 1980). If a cell synthesized
O6guanine alkyl transferase (MER+ phenotype) the
monoadducts on O6guanine are removed, thus
preventing the formation of DNA-ISC. In contrast,
in a cell which is O0guanine repair-deficient
(MER- phenotype) the monoadduct is not
removed and can form DNA-ISC. Both chloro-
ethylnitrosoureas and M induced DNA-ISC appear
related to their cytotoxicity (Gibson et al., 1984b).
However some differences which may perhaps
underlie the different perturbation in the cell cycle
phases were suggested by Gibson et al. (1984a,b).
They found that M formed DNA-ISC more slowly
than chloroethylnitrosoureas. In addition M caused
much greater differential cytotoxicity between
O6alkylguanine repair proficient (MER' pheno-
type) and deficient (MER- phenotype) cells,
suggesting that it forms more O6guanine adducts
than BCNU.
Even though these differences are of biochemicalMITOZOLOMIDE ACTIVITY ON HUMAN CANCER CELLS 931
Table III Effects of M on the distribution in GI, S early (SE), S middle (SM), and S late +G2+Mitosis
(SLG2M) and on [3H]-TdR incorporation of human ovarian cancer cells (growing in primary culture) derived
from patients previously treated with antineoplastic agents. Cells were treated for 24h.
Mitozolomide [3H]-TdR
Pt. no. Sample G1 SE SM SLG2M pgml- DNA index % ofcontrol
8 Ascitic fluid 52 12 10 26 control 1.79
55 10 11 24 0.1 100
53 10 11 26 1 100
47 10 11 32 10 75a
9 Ascitic fluid 85 3 3 9 control 1.00
82 3 4 11 0.1 100
84 4 3 9 1 100
83 4 4 9 10 100
9a Ascitic fluid 36 14 14 36 control 1.00
43 14 16 27 0.1 90
36 15 17 32 1 82
34 14 16 36 10 82
10 Ascitic fluid 35 13 20 22 control 1.57
30 14 22 34 0.1 100
29 16 22 33 1 100
28 22 27 23 10 100
11 Primary tumour 86 1 1 12 control 1.00
88 1 1 10 1 100
83 2 1 14 10 76
1la Metastasis 66 3 4 27 control 1.00
66 2 4 28 1
65 2 4 29 10
12 Ascitic fluid 67 7 7 20 control 0.90
40 9 10 41 10
13 Ascitic fluid 56 14 12 18 control 1.67
55 14 13 18 0.1
55 13 12 20 1
51 15 15 19 10
DNA index was determined as described in Mater
test. aP<0.05; bP<0.01.
interest, their relevance to possible contrasting
pharmacological effects is questionable since in
rodent tumours M and chloroethylnitrosoureas
showed a similar spectrum of activity (Hickman et
al., 1985) and were cross resistant (Gibson, 1982).
In the present studies the cytotoxicity of M and
BCNU against M14 and SW626 human cell lines
was also similar.
The indication arising during phase I clinical
trials that M might be active against human
ovarian carcinoma (Newlands et al., 1985)
prompted us to investigate whether human ovarian
epithelial cancer cells from biopsies of primary
tumours or metastases or from ascitic fluids were
sensitive to this agent. Using flow cytometry
analysis, a method with proven sensitivity in
detecting antiproliferative properties of this drug,
we assessed whether M caused cell cycle pertur-
bation on 16 primary cultures of ovarian carcinoma
from 13 patients. M was only effective in one case
in which a moderate accumulation of cells in S
rials and methods. Statistical analysis was by Dunnett's
phase was seen. We did not test drug concen-
trations higher than 10,gml-l since a plasma peak
level of 7gml-1 M was reported after the dose of
250mgkg-1, i.e. higher than that recommended as
safe for further clinical investigations (Newlands et
al., 1985).
Since none of the patients had previously
received drugs related to M (i.e. triazenes or
nitrosoureas) it may be excluded that resistance was
induced by previous treatment, and it appears more
likely that ovarian carcinoma cells are naturally
non-susceptible to this drug.
Whether this lack of sensitivity is due to these
cells' ability to remove 06alkylguanine adducts
from DNA or to other mechanisms is now being
investigated in our laboratories.
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